Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 529

1.

Role of Type I and II Interferons in Colorectal Cancer and Melanoma.

Di Franco S, Turdo A, Todaro M, Stassi G.

Front Immunol. 2017 Jul 26;8:878. doi: 10.3389/fimmu.2017.00878. eCollection 2017. Review.

2.

Neither epithelial nor mesenchymal circulating tumor cells isolated from breast cancer patients are tumorigenic in NOD-scid Il2rgnull mice.

Donnenberg VS, Huber A, Basse P, Rubin JP, Donnenberg AD.

NPJ Breast Cancer. 2016 Mar 9;2:16004. doi: 10.1038/npjbcancer.2016.4. eCollection 2016.

3.

Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity.

Wainwright EN, Scaffidi P.

Trends Cancer. 2017 May;3(5):372-386. doi: 10.1016/j.trecan.2017.04.004. Epub 2017 May 5. Review.

4.

Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?

Gampa G, Vaidhyanathan S, Sarkaria JN, Elmquist WF.

Pharmacol Res. 2017 Sep;123:10-25. doi: 10.1016/j.phrs.2017.06.008. Epub 2017 Jun 17.

PMID:
28634084
5.

PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.

Almozyan S, Colak D, Mansour F, Alaiya A, Al-Harazi O, Qattan A, Al-Mohanna F, Al-Alwan M, Ghebeh H.

Int J Cancer. 2017 Oct 1;141(7):1402-1412. doi: 10.1002/ijc.30834. Epub 2017 Jun 30.

PMID:
28614911
6.

The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma.

Ignatius MS, Hayes MN, Lobbardi R, Chen EY, McCarthy KM, Sreenivas P, Motala Z, Durbin AD, Molodtsov A, Reeder S, Jin A, Sindiri S, Beleyea BC, Bhere D, Alexander MS, Shah K, Keller C, Linardic CM, Nielsen PG, Malkin D, Khan J, Langenau DM.

Cell Rep. 2017 Jun 13;19(11):2304-2318. doi: 10.1016/j.celrep.2017.05.061.

7.

Combinatorial Discovery of Defined Substrates That Promote a Stem Cell State in Malignant Melanoma.

Zhang D, Lee J, Sun MB, Pei Y, Chu J, Gillette MU, Fan TM, Kilian KA.

ACS Cent Sci. 2017 May 24;3(5):381-393. doi: 10.1021/acscentsci.6b00329. Epub 2017 Apr 26.

8.

Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts.

Ball CR, Oppel F, Ehrenberg KR, Dubash TD, Dieter SM, Hoffmann CM, Abel U, Herbst F, Koch M, Werner J, Bergmann F, Ishaque N, Schmidt M, von Kalle C, Scholl C, Fröhling S, Brors B, Weichert W, Weitz J, Glimm H.

EMBO Mol Med. 2017 Jul;9(7):918-932. doi: 10.15252/emmm.201607354.

9.

Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.

Eskiocak B, McMillan EA, Mendiratta S, Kollipara RK, Zhang H, Humphries CG, Wang C, Garcia-Rodriguez J, Ding M, Zaman A, Rosales TI, Eskiocak U, Smith MP, Sudderth J, Komurov K, Deberardinis RJ, Wellbrock C, Davies MA, Wargo JA, Yu Y, De Brabander JK, Williams NS, Chin L, Rizos H, Long GV, Kittler R, White MA.

Cancer Discov. 2017 Aug;7(8):832-851. doi: 10.1158/2159-8290.CD-16-0955. Epub 2017 Apr 28.

PMID:
28455392
10.

Silencing PRDM14 expression by an innovative RNAi therapy inhibits stemness, tumorigenicity, and metastasis of breast cancer.

Taniguchi H, Hoshino D, Moriya C, Zembutsu H, Nishiyama N, Yamamoto H, Kataoka K, Imai K.

Oncotarget. 2017 Jul 18;8(29):46856-46874. doi: 10.18632/oncotarget.16776.

11.

NK cells control breast cancer and related cancer stem cell hematological spread.

Tallerico R, Conti L, Lanzardo S, Sottile R, Garofalo C, Wagner AK, Johansson MH, Cristiani CM, Kärre K, Carbone E, Cavallo F.

Oncoimmunology. 2017 Feb 23;6(3):e1284718. doi: 10.1080/2162402X.2017.1284718. eCollection 2017.

12.

Serotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts.

Gwynne WD, Hallett RM, Girgis-Gabardo A, Bojovic B, Dvorkin-Gheva A, Aarts C, Dias K, Bane A, Hassell JA.

Oncotarget. 2017 May 9;8(19):32101-32116. doi: 10.18632/oncotarget.16646.

13.

Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.

Frankel AE, Eskiocak U, Gill JG, Yuan S, Ramesh V, Froehlich TW, Ahn C, Morrison SJ.

Neoplasia. 2017 Apr;19(4):255-260. doi: 10.1016/j.neo.2017.01.010. Epub 2017 Mar 6.

14.

Metastatic State of Cancer Cells May Be Indicated by Adhesion Strength.

Fuhrmann A, Banisadr A, Beri P, Tlsty TD, Engler AJ.

Biophys J. 2017 Feb 28;112(4):736-745. doi: 10.1016/j.bpj.2016.12.038.

PMID:
28256233
15.

Tumor-Initiating Cells: a criTICal review of isolation approaches and new challenges in targeting strategies.

Qureshi-Baig K, Ullmann P, Haan S, Letellier E.

Mol Cancer. 2017 Feb 16;16(1):40. doi: 10.1186/s12943-017-0602-2. Review.

16.

Epigenetics in cancer stem cells.

Toh TB, Lim JJ, Chow EK.

Mol Cancer. 2017 Feb 1;16(1):29. doi: 10.1186/s12943-017-0596-9. Review.

17.

Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma.

Kumar D, Gorain M, Kundu G, Kundu GC.

Mol Cancer. 2017 Jan 30;16(1):7. doi: 10.1186/s12943-016-0578-3. Review.

18.

Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.

Winterhoff BJ, Maile M, Mitra AK, Sebe A, Bazzaro M, Geller MA, Abrahante JE, Klein M, Hellweg R, Mullany SA, Beckman K, Daniel J, Starr TK.

Gynecol Oncol. 2017 Mar;144(3):598-606. doi: 10.1016/j.ygyno.2017.01.015. Epub 2017 Jan 19.

PMID:
28111004
19.

A new model of multi-visceral and bone metastatic prostate cancer with perivascular niche targeting by a novel endothelial specific adenoviral vector.

Lu ZH, Kaliberov S, Sohn RE, Kaliberova L, Du Y, Prior JL, Leib DJ, Chauchereau A, Sehn JK, Curiel DT, Arbeit JM.

Oncotarget. 2017 Feb 14;8(7):12272-12289. doi: 10.18632/oncotarget.14699.

20.

In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells.

Madorsky Rowdo FP, Barón A, von Euw EM, Mordoh J.

Oncol Rep. 2017 Mar;37(3):1367-1378. doi: 10.3892/or.2017.5363. Epub 2017 Jan 13.

Supplemental Content

Support Center